JP2024059609A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024059609A5 JP2024059609A5 JP2023214174A JP2023214174A JP2024059609A5 JP 2024059609 A5 JP2024059609 A5 JP 2024059609A5 JP 2023214174 A JP2023214174 A JP 2023214174A JP 2023214174 A JP2023214174 A JP 2023214174A JP 2024059609 A5 JP2024059609 A5 JP 2024059609A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- seq
- antigen
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063051172P | 2020-07-13 | 2020-07-13 | |
| US63/051,172 | 2020-07-13 | ||
| US202163154531P | 2021-02-26 | 2021-02-26 | |
| US63/154,531 | 2021-02-26 | ||
| JP2023501559A JP2023534437A (ja) | 2020-07-13 | 2021-07-12 | タンパク質中のグルタミン残基にコンジュゲートされたカンプトテシンアナログおよびその使用 |
| PCT/US2021/041304 WO2022015656A1 (en) | 2020-07-13 | 2021-07-12 | Camptothecin analogs conjugated to a glutamine residue in a protein, and their use |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023501559A Division JP2023534437A (ja) | 2020-07-13 | 2021-07-12 | タンパク質中のグルタミン残基にコンジュゲートされたカンプトテシンアナログおよびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024059609A JP2024059609A (ja) | 2024-05-01 |
| JP2024059609A5 true JP2024059609A5 (OSRAM) | 2024-07-23 |
| JP7776485B2 JP7776485B2 (ja) | 2025-11-26 |
Family
ID=77168491
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023501559A Pending JP2023534437A (ja) | 2020-07-13 | 2021-07-12 | タンパク質中のグルタミン残基にコンジュゲートされたカンプトテシンアナログおよびその使用 |
| JP2023214174A Active JP7776485B2 (ja) | 2020-07-13 | 2023-12-19 | タンパク質中のグルタミン残基にコンジュゲートされたカンプトテシンアナログおよびその使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023501559A Pending JP2023534437A (ja) | 2020-07-13 | 2021-07-12 | タンパク質中のグルタミン残基にコンジュゲートされたカンプトテシンアナログおよびその使用 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20220072141A1 (OSRAM) |
| EP (2) | EP4178625A1 (OSRAM) |
| JP (2) | JP2023534437A (OSRAM) |
| KR (2) | KR20230038738A (OSRAM) |
| CN (2) | CN118085100A (OSRAM) |
| AU (2) | AU2021308190A1 (OSRAM) |
| BR (1) | BR112023000489A2 (OSRAM) |
| CA (1) | CA3183184A1 (OSRAM) |
| CL (1) | CL2023000098A1 (OSRAM) |
| CO (1) | CO2023001402A2 (OSRAM) |
| IL (2) | IL309173A (OSRAM) |
| MA (1) | MA71650A (OSRAM) |
| MX (2) | MX2023000544A (OSRAM) |
| WO (1) | WO2022015656A1 (OSRAM) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230097908A1 (en) * | 2020-01-22 | 2023-03-30 | Medimmune Limited | Compounds and conjugates thereof |
| CN115925796B (zh) * | 2020-09-30 | 2024-05-31 | 映恩生物制药（苏州）有限公司 | 一种抗肿瘤化合物及其制备方法和应用 |
| JP2025502147A (ja) * | 2022-01-12 | 2025-01-24 | リジェネロン ファーマシューティカルズ，インク． | タンパク質中のグルタミン残基にコンジュゲートしたカンプトテシンアナログおよびその使用 |
| CN118591524A (zh) * | 2022-01-24 | 2024-09-03 | 北京桦冠生物技术有限公司 | 缀合物及其用途 |
| WO2023172968A1 (en) * | 2022-03-09 | 2023-09-14 | Merck Patent Gmbh | Anti-gd2 antibodies, immunoconjugates and therapeutic uses thereof |
| TW202344252A (zh) * | 2022-05-09 | 2023-11-16 | 大陸商同宜醫藥（蘇州）有限公司 | 一種喜樹鹼衍生物，基於其的抗體－藥物偶聯物和藥物組成物，及其應用 |
| WO2024008102A1 (en) * | 2022-07-05 | 2024-01-11 | Wuxi Xdc (Shanghai) Co., Ltd. | Linker for conjugation |
| KR20250054842A (ko) | 2022-07-29 | 2025-04-23 | 리제너론 파마슈티칼스 인코포레이티드 | 뇌 및 근육으로의 트랜스페린 수용체(tfr)-매개 전달을 위한 조성물 및 방법 |
| IL319866A (en) * | 2022-09-30 | 2025-05-01 | Beigene Switzerland Gmbh | Ligand-drug conjugates of exatacan analogs and their medical use |
| WO2024107765A2 (en) | 2022-11-14 | 2024-05-23 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for fibroblast growth factor receptor 3-mediated delivery to astrocytes |
| AU2023407365A1 (en) * | 2022-12-21 | 2025-07-31 | Regeneron Pharmaceuticals, Inc. | Prodrugs of topoisomerase i inhibitor for adc conjugations and methods of use thereof |
| CN121001751A (zh) | 2023-02-09 | 2025-11-21 | 里珍纳龙药品有限公司 | 借助逆电子需求狄尔斯-阿尔德反应的抗体-药物缀合物 |
| WO2025014533A1 (en) | 2023-07-10 | 2025-01-16 | Regeneron Pharmaceuticals, Inc. | Anti-human cacng1 antibody-drug conjugates and uses thereof |
| WO2025038752A1 (en) * | 2023-08-14 | 2025-02-20 | Cancer Targeted Technology Llc | Psma binding ligand-linker conjugates and methods for use thereof |
| EP4537854A1 (en) * | 2023-10-04 | 2025-04-16 | Formosa Laboratories, Inc. | Compound for conjugation, conjugate and pharmaceutical composition comprising the same |
| WO2025078841A2 (en) | 2023-10-11 | 2025-04-17 | Antikor Biopharma Limited | Antibodies, conjugates, and uses thereof |
| WO2025103474A1 (zh) * | 2023-11-17 | 2025-05-22 | 成都康弘生物科技有限公司 | 双毒素抗体药物偶联物及其用途 |
| WO2025199666A1 (en) * | 2024-03-25 | 2025-10-02 | Canwell Biotech Limited | Multivalent linkers for high loading antibody-drug conjugates, and compositions and methods thereof |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| CA2008368C (en) | 1989-01-24 | 2003-04-08 | Jeffrey Greve | Soluble molecule related to but distinct from icam-1 |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| CA2103059C (en) | 1991-06-14 | 2005-03-22 | Paul J. Carter | Method for making humanized antibodies |
| US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
| US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US20070258987A1 (en) | 2000-11-28 | 2007-11-08 | Seattle Genetics, Inc. | Recombinant Anti-Cd30 Antibodies and Uses Thereof |
| EP1572916A4 (en) | 2002-04-05 | 2007-05-30 | Agensys Inc | NUCLEIC ACID AND CORRESPONDING PROTEIN WITH THE NAME 98P4B6, SUITABLE FOR THE TREATMENT AND DETECTION OF CANCER |
| WO2005079490A2 (en) | 2004-02-13 | 2005-09-01 | Nuvelo, Inc. | Methods of therapy and diagnosis using targeting of cells that express steap2 polypeptides |
| TW200539855A (en) | 2004-03-15 | 2005-12-16 | Wyeth Corp | Calicheamicin conjugates |
| CA2567520A1 (en) | 2004-06-01 | 2005-12-15 | Genentech, Inc. | Maytansinoid-antibody conjugates |
| CA2587589A1 (en) | 2004-11-29 | 2006-06-22 | Seattle Genetics, Inc. | Engineered antibodies and immunoconjugates |
| US7750116B1 (en) | 2006-02-18 | 2010-07-06 | Seattle Genetics, Inc. | Antibody drug conjugate metabolites |
| NO347649B1 (no) | 2006-12-14 | 2024-02-12 | Regeneron Pharma | Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse. |
| WO2008122039A2 (en) | 2007-04-02 | 2008-10-09 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Selenocysteine mediated hybrid antibody molecules |
| JP2010528285A (ja) | 2007-05-23 | 2010-08-19 | ベンタナ・メデイカル・システムズ・インコーポレーテツド | 免疫組織化学およびｉｎｓｉｔｕハイブリダーゼーションのためのポリマー担体 |
| CN102083461B (zh) | 2008-04-30 | 2014-09-17 | 伊缪诺金公司 | 有效的偶联物和亲水性连接体 |
| US8969626B2 (en) | 2008-07-21 | 2015-03-03 | Polytherics Limited | Reagents and method for conjugating biological molecules |
| JO3182B1 (ar) | 2009-07-29 | 2018-03-08 | Regeneron Pharma | مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2 |
| DK2549276T3 (en) | 2009-08-10 | 2015-06-08 | Ucl Business Plc | Reversible, covalent bonding of functional molecules |
| HRP20130953T1 (hr) | 2010-04-15 | 2013-11-22 | Spirogen Sàrl | Pirolobenzodiazepini i njihovi konjugati |
| WO2012005982A2 (en) | 2010-07-06 | 2012-01-12 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Reporter for rna polymerase ii termination |
| CA2807282A1 (en) | 2010-08-02 | 2012-02-09 | Regeneron Pharamaceuticals, Inc. | Mice that make binding proteins comprising vl domains |
| SG10201605293PA (en) | 2011-05-27 | 2016-08-30 | Ambrx Inc | Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives |
| US8815226B2 (en) | 2011-06-10 | 2014-08-26 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
| BR112014009070B1 (pt) | 2011-10-14 | 2021-11-23 | Medimmune Limited | Método de síntese e intermediários úteis na preparação de pirrolobenzo-diazepinas |
| CN103998450B (zh) | 2011-10-14 | 2017-03-08 | 麦迪穆有限责任公司 | 吡咯并苯并二氮杂卓 |
| CA2850373C (en) | 2011-10-14 | 2019-07-16 | Seattle Genetics, Inc. | Pyrrolobenzodiazepines and targeted conjugates |
| WO2013068874A1 (en) | 2011-11-11 | 2013-05-16 | Pfizer Inc. | Antibody-drug conjugates |
| CA2857398A1 (en) | 2011-12-05 | 2013-06-13 | Igenica Biotherapeutics, Inc. | Antibody-drug conjugates and related compounds, compositions, and methods |
| RU2582259C2 (ru) * | 2012-02-24 | 2016-04-20 | Алтеоген Инк. | Модифицированные антитела, с которыми связан мотив, включающий остаток цистеина, конъюгаты этих модифицированных антител с лекарственными веществами и способ их получения |
| KR102237639B1 (ko) | 2012-10-11 | 2021-04-07 | 다이이찌 산쿄 가부시키가이샤 | 항체-약물 콘주게이트 |
| SMT202300208T1 (it) | 2012-10-23 | 2023-09-06 | Synaffix Bv | Anticorpo modificato, coniugato di anticorpo e processo per la preparazione degli stessi |
| JP6744212B2 (ja) * | 2013-06-21 | 2020-08-19 | イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． | ポリペプチドの酵素的結合 |
| MX373528B (es) | 2013-08-26 | 2020-04-21 | Regeneron Pharma | Composiciones farmacéuticas que contienen diasterómeros macrólidos, métodos para su síntesis y usos terapéuticos. |
| PH12020552271A1 (en) * | 2014-01-31 | 2022-05-02 | Daiichi Sankyo Co Ltd | Anti-her2 antibody-drug conjugate |
| JP2017114763A (ja) * | 2014-03-26 | 2017-06-29 | 第一三共株式会社 | 抗ｃｄ９８抗体−薬物コンジュゲート |
| DK3129063T3 (da) * | 2014-04-10 | 2021-04-06 | Daiichi Sankyo Co Ltd | Anti-her3-antistof-lægemiddelkonjugat |
| JP6800021B2 (ja) | 2014-06-02 | 2020-12-16 | レゲネロン ファーマシューティカルス，インコーポレーテッド | 抗体−薬物コンジュゲート、それらの製造、及びそれらの治療用途 |
| TWI710573B (zh) * | 2015-01-26 | 2020-11-21 | 美商再生元醫藥公司 | 抗伊波拉病毒醣蛋白之人類抗體 |
| JP6826055B2 (ja) * | 2015-03-13 | 2021-02-03 | サイトメックス セラピューティクス インコーポレイテッド | 抗ｐｄｌ１抗体、活性化可能抗ｐｄｌ１抗体、およびその使用方法 |
| KR101757977B1 (ko) | 2015-06-26 | 2017-07-13 | 아주대학교산학협력단 | 바이오 잉크의 제조방법 및 3d 프린터 적용 |
| EA039072B9 (ru) | 2016-01-25 | 2022-02-04 | Регенерон Фармасьютикалз, Инк. | Производные майтанзиноида, их конъюгаты и способы применения |
| WO2017147542A2 (en) | 2016-02-26 | 2017-08-31 | Regeneron Pharmaceuticals, Inc. | Optimized transglutaminase site-specific antibody conjugation |
| MX2019003325A (es) | 2016-09-23 | 2019-08-05 | Regeneron Pharma | Anticuerpos anti-steap2, conjugados anticuerpo-farmaco, y moleculas de fijacion al antigeno biespecificas que se fijan a steap2 y cd3, y usos de estos. |
| MX394528B (es) * | 2016-11-08 | 2025-03-24 | Regeneron Pharma | Esteroides y conjugados de proteinas de los mismos. |
| TWI782930B (zh) * | 2016-11-16 | 2022-11-11 | 美商再生元醫藥公司 | 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法 |
| WO2018182341A1 (ko) | 2017-03-29 | 2018-10-04 | 주식회사 레고켐 바이오사이언스 | 피롤로벤조디아제핀 이량체 전구체 및 이의 리간드-링커 접합체 화합물 |
| AU2018269568B2 (en) * | 2017-05-18 | 2022-03-24 | Regeneron Pharmaceuticals, Inc. | Bis-octahydrophenanthrene carboxamides and protein conjugates thereof |
| CN111065623B9 (zh) | 2017-05-24 | 2024-10-25 | 德克萨斯州大学系统董事会 | 用于抗体药物缀合物的接头 |
| AU2018289581C1 (en) * | 2017-06-23 | 2025-01-30 | VelosBio Inc. | ROR1 antibody immunoconjugates |
| MX2020011487A (es) | 2018-04-30 | 2020-12-07 | Regeneron Pharma | Anticuerpos y moleculas biespecificas de union al antigeno que se unen a her2 y/o aplp2, conjugados y usos de estos. |
| SG11202010909RA (en) * | 2018-05-09 | 2020-12-30 | Regeneron Pharma | Anti-msr1 antibodies and methods of use thereof |
| US12479926B2 (en) * | 2018-05-18 | 2025-11-25 | Daiichi Sankyo Co., Ltd. | Anti-MUC1 antibody-drug conjugate |
| BR112021009673A2 (pt) * | 2018-11-20 | 2021-12-14 | Regeneron Pharma | Derivados de bis-octa-hidrofenantreno carboxamida e conjugados de proteínas dos mesmos para uso como agonistas de lxr |
| WO2020245229A1 (en) * | 2019-06-03 | 2020-12-10 | Synaffix B.V. | Acetal-based cleavable linkers |
| CN110974975B (zh) * | 2019-12-12 | 2023-10-20 | 成都百利多特生物药业有限责任公司 | 一种快速释放的抗体药物偶联物 |
| CA3166619A1 (en) * | 2020-02-28 | 2021-09-02 | Julian Andreev | Bispecific antigen binding molecules that bind her2, and methods of use thereof |
-
2021
- 2021-07-12 BR BR112023000489A patent/BR112023000489A2/pt unknown
- 2021-07-12 CN CN202410175152.9A patent/CN118085100A/zh active Pending
- 2021-07-12 IL IL309173A patent/IL309173A/en unknown
- 2021-07-12 JP JP2023501559A patent/JP2023534437A/ja active Pending
- 2021-07-12 KR KR1020237004637A patent/KR20230038738A/ko active Pending
- 2021-07-12 US US17/373,524 patent/US20220072141A1/en active Pending
- 2021-07-12 EP EP21749495.4A patent/EP4178625A1/en active Pending
- 2021-07-12 MA MA71650A patent/MA71650A/fr unknown
- 2021-07-12 KR KR1020247008244A patent/KR20240038138A/ko active Pending
- 2021-07-12 CA CA3183184A patent/CA3183184A1/en active Pending
- 2021-07-12 IL IL299153A patent/IL299153A/en unknown
- 2021-07-12 WO PCT/US2021/041304 patent/WO2022015656A1/en not_active Ceased
- 2021-07-12 AU AU2021308190A patent/AU2021308190A1/en active Pending
- 2021-07-12 MX MX2023000544A patent/MX2023000544A/es unknown
- 2021-07-12 EP EP24176032.1A patent/EP4406608A3/en active Pending
- 2021-07-12 CN CN202180062762.2A patent/CN116390771A/zh active Pending
-
2023
- 2023-01-10 MX MX2024003180A patent/MX2024003180A/es unknown
- 2023-01-10 CL CL2023000098A patent/CL2023000098A1/es unknown
- 2023-02-09 CO CONC2023/0001402A patent/CO2023001402A2/es unknown
- 2023-11-21 US US18/516,454 patent/US20240252661A1/en active Pending
- 2023-12-19 JP JP2023214174A patent/JP7776485B2/ja active Active
-
2024
- 2024-02-09 AU AU2024200822A patent/AU2024200822A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024059609A5 (OSRAM) | ||
| JP2020019787A5 (OSRAM) | ||
| US20210024635A1 (en) | Anti-wt1/hla-specific antibodies | |
| JP2019532056A5 (OSRAM) | ||
| JP2019069983A (ja) | 新規抗体コンジュゲートおよびその使用 | |
| JP2017534253A5 (OSRAM) | ||
| RU2007133108A (ru) | АНТИТЕЛА, СВЯЗЫВАЮЩИЕСЯ С EphA2, И МЕТОДЫ ИХ ИСПОЛЬЗОВАНИЯ | |
| JP2012522513A5 (OSRAM) | ||
| JP2008529497A5 (OSRAM) | ||
| RU2015116480A (ru) | Анти-notch3 антитела и конъюганты антител с лекарственным средством | |
| RU2011144119A (ru) | АНТИТЕЛА К FcRH5, ИХ ИММУНОКОНЪЮГАТЫ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
| JPWO2019246514A5 (OSRAM) | ||
| JP2016509014A (ja) | 新規の多特異的構成物 | |
| RU2011144141A (ru) | АНТИТЕЛА К FcRH5, ИХ ИММУНОКОНЪЮГАТЫ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
| RU2014113304A (ru) | Анти-cd40-антитела, применение и методы | |
| EP1470146A2 (en) | Antibodies against the muc18 antigen | |
| RU2011103125A (ru) | КОМБИНАЦИЯ АНТАГОНИСТА c-Met И АМИНОГЕТЕРОАРИЛА ДЛЯ ЛЕЧЕНИЯ РАКА | |
| CN113710271A (zh) | 抗cd228抗体和抗体-药物缀合物 | |
| WO2022171134A1 (zh) | 包含抗cldn18.2的抗体或其抗原结合片段的抗体药物偶联物及其用途 | |
| CN119136840A (zh) | 喜树碱类衍生物及配体-药物偶联物 | |
| WO2023071676A1 (zh) | 一种抗her2/抗pd-l1双功能抗体及其应用 | |
| US10611847B2 (en) | ABCG2 monoclonal antibody and uses thereof | |
| JP2025524306A (ja) | Ｉｔｇａ２を標的とする抗体及びそれを含む抗体薬物複合体 | |
| JPWO2022087243A5 (OSRAM) | ||
| JPWO2019212965A5 (OSRAM) |